Search

News Do Gliflozins Affect the Need to Use Diuretics?

Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to antidiabetics with proven cardioprotective effects and additional indications for patients with heart failure or chronic kidney disease. Last year, the CHAMPION cohort study was published, which investigated the impact of empagliflozin use on diuretic prescribing and mid-term laboratory results in patients concurrently treated with diuretics.

Source: Heart Failure 1. 10. 2023

News Romiplostim in Newly Diagnosed ITP Resistant to 1st Line Treatment –⁠ Case Study

In patients with immune thrombocytopenia (ITP), effectively stopping and controlling bleeding can be complicated in some cases. This includes scenarios such as open wounds. One way to stabilize platelet count can be through administering a thrombopoietin receptor agonist (TPO-RA). The following case study presents a successful treatment of newly diagnosed ITP.

Source: Immune Thrombocytopenia 2. 10. 2023

News Romiplostim in ITP Treatment –⁠ Data from German Clinical Practice

Real-world clinical practice data from Germany confirm the beneficial effect and safety profile of romiplostim in patients with immune thrombocytopenia (ITP), both newly diagnosed, persistent, and chronic.

Source: Immune Thrombocytopenia 2. 10. 2023

News Invasive Pneumococcal Disease –⁠ Current Czech Data

The number of reported cases of invasive pneumococcal disease (IPD) returned to levels comparable to those before the COVID-19 pandemic in 2022. Regarding age-specific morbidity, the most at-risk groups are children under 1 year of age and seniors over 65 years old. The specific data for 2022 is provided by a report from the Center for Epidemiology and Microbiology of the National Institute of Public Health (SZÚ).

Source: Regular Vaccination 2. 10. 2023

News Physical Activity in Young Men with Hemophilia A

What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.

Source: Hemophilia with Movement 6. 10. 2023

News N9-GP in Previously Treated Pediatric Patients with Hemophilia B –⁠ Extended Follow-up

An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.

Source: Hemophilia with Movement 4. 10. 2023

News Side Effects of Antipsychotics and Patient Preferences in the Treatment of Schizophrenia

Although a number of antipsychotics are currently available, many patients still suffer from unpleasant side effects associated with the treatment of schizophrenia. To determine how individuals with schizophrenia and schizoaffective disorders perceive antipsychotic treatment, a larger survey was conducted in the USA in 2016.

Source: Modern Treatment of Schizophrenia 9. 10. 2023

News Ocrelizumab in the treatment of multiple sclerosis in real-world practice –⁠ a systematic review of published studies

In controlled study programs, ocrelizumab has demonstrated beneficial effects on improving clinical parameters in patients with multiple sclerosis, such as the annual relapse rate or confirmed disability progression. However, to get a complete picture of its clinical benefit, real-world evidence in a broad patient population is also needed. A systematic review of real-world clinical practice studies with ocrelizumab, published in March 2023, demonstrates its benefits in patients with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in terms of relapse frequency, disease activity on MRI, disability, absence of disease activity (NEDA), and quality of life.

Source: Neurology - Multiple Sclerosis 27. 9. 2023

News INFOGRAPHIC: Post-Induction Therapy for AML –⁠ Current Guidelines

What are the recommended therapeutic modalities for consolidation and maintenance therapy of acute myeloid leukemia (AML) in patients over 60 years of age? We present a clear therapeutic algorithm according to the current recommendations of the American National Comprehensive Cancer Network.

Source: Acute Myeloid Leukemia 10. 10. 2023

News Oral Azacitidine After Achieving Remission in AML Improves Survival and Does Not Worsen Quality of Life

Orally administered azacitidine as maintenance therapy in patients with acute myeloid leukemia (AML) after achieving remission provides a favorable effect in terms of fatigue and improving health-related quality of life (HRQoL). This is based on the results of the QUAZAR AML-001 study, which were published in the journal Haematologica.

Source: Acute Myeloid Leukemia 10. 10. 2023

News Improvement of Executive Functions in Therapy of Dravet Syndrome with Fenfluramine in Preschool Children

Dravet syndrome is a rare genetic progressive epileptic encephalopathy that is usually accompanied by intellectual and behavioral disorders. Many children with this syndrome also struggle with deficits in executive functions. An analysis recently published in the journal Epilepsy & Behavior assessed the impact of fenfluramine therapy on executive functions in preschool children with this condition.

Source: Rare Diseases in Neurology 10. 10. 2023

News Myasthenia Gravis and Unmet Patient Needs –⁠ Data from Clinical Practice

Myasthenia gravis (MG) is a rare, chronic, disabling, unpredictable, and potentially life-threatening autoimmune neuromuscular disease. There is still a lack of sufficient data from real clinical practice to better meet the needs of MG patients. What is the current situation in European countries? And how are Czech patients doing?

Source: Rare Diseases in Neurology 10. 10. 2023

News Streptococcus pneumoniae Serotype 3 Continues to Be the Most Frequent Cause of Invasive Pneumococcal Diseases in the Czech Republic

After 2 years influenced by the COVID-19 pandemic, the number of cases of invasive pneumococcal diseases (IPD) has returned to pre-2020 levels. Serotype 3 remains the most frequent cause of IPD for the twelfth consecutive year.

Source: Regular Vaccination 26. 10. 2023

News Benefit of Adding Panitumumab to Maintenance Therapy in mCRC with Non-mutated RAS Oncogene

PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to maintenance therapy with fluorouracil and folic acid (FU/FA) in patients with previously untreated metastatic colorectal cancer (mCRC) with a non-mutated (wt −⁠ wild-type) RAS oncogene. The results suggest that upon achieving disease control after initial treatment with FOLFOX + panitumumab, the combination of panitumumab with FU/FA might be the most suitable for maintenance therapy.

Source: Colorectal Cancer 14. 10. 2023

News Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency –⁠ Real-World Data

Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy. The study presented below summarizes real-world data concerning the latest substitution method (i.e., facilitated subcutaneous administration) in paediatric patients.

Source: Primary and Secondary Immunodeficiencies 16. 10. 2023